**Supplementary Fig. 1a** Progression-free survival of patients who received T-DM1 treatment.

Median progression-free survival with T-DM1 was 3.7 (95% CI 2.7–5.5) months.

T-DM1, trastuzumab emtansine.



T-DM1 PFS n=30

 サンプル数 生存期間中央値 95%信頼区間

1 30 3.64931506849315 2.72876712328767-5.52328767123288